Thuja Capital invests in Utrecht UMC spin-off EnCare Biotech BV

Date: 17/11/2014

17 November 2014, Utrecht – EnCare Biotech B.V., a newly founded spin-off company from University Medical Center Utrecht, has successfully closed a Series A financing round of EUR 5.5 M to develop an innovative therapy for the prevention of chronic heart failure after a myocardial infarction.

The investment was made by Index Ventures (CH, UK & USA) and Thuja Capital as lead investors. The investment company of UMC Utrecht and Utrecht University, Utrecht Holdings, also participated.

Michèle Ollier (partner with Index Ventures), Harrold van Barlingen (managing partner with Thuja Capital) and Oscar Schoots (managing director of Utrecht Holdings) will take a director’s seat in the Supervisory Board of EnCare.

A press release can be found here (Dutch version).